Development of a humanized antibody with high therapeutic potential against dengue virus type 2.

Development of a humanized antibody with high therapeutic potential against dengue virus type 2.

BACKGROUND: Dengue virus (DENV) is a significant public health threat in tropical and subtropical regions of the world. A therapeutic antibody against the viral envelope (E) protein represents a promising immunotherapy for disease control. METHODOLOGY/PRINCIPAL FINDINGS: We generated seventeen novel...

Full description

Bibliographic Details
Main Authors:	Pi-Chun Li, Mei-Ying Liao, Ping-Chang Cheng, Jian-Jong Liang, I-Ju Liu, Chien-Yu Chiu, Yi-Ling Lin, Gwong-Jen J Chang, Han-Chung Wu
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS Neglected Tropical Diseases
Online Access:	http://europepmc.org/articles/PMC3341331?pdf=render

Similar Items

Correction: Development of a Humanized Antibody with High Therapeutic Potential against Dengue Virus Type 2.
by: Pi-Chun Li, et al.
Published: (2024-03-01)

Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement
by: Hughes Holly R, et al.
Published: (2012-06-01)

Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody
by: Wen-Fan Shen, et al.
Published: (2018-10-01)

Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay.
by: Hong-En Lin, et al.
Published: (2012-01-01)

Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse model.
by: Sen-Mao Tien, et al.
Published: (2022-04-01)

Molecular and Epidemiologic Analysis of Dengue Virus Isolates from Somalia
by: Niranjan Kanesa-thasan, et al.
Published: (1998-06-01)

Comparative analysis of full genomic sequences among different genotypes of dengue virus type 3
by: Lin Ting-Hsiang, et al.
Published: (2008-05-01)

Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens.
by: Wayne D Crill, et al.
Published: (2009-01-01)

Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis
by: Yi-Ling Cheng, et al.
Published: (2022-08-01)

Improving dengue viral antigens detection in dengue patient serum specimens using a low pH glycine buffer treatment
by: Wen-Fan Shen, et al.
Published: (2017-04-01)

Strategically examining the full-genome of dengue virus type 3 in clinical isolates reveals its mutation spectra
by: Wu Hui-Lin, et al.
Published: (2005-08-01)

Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.
by: Yi-Chin Fan, et al.
Published: (2012-01-01)

Antibodies against dengue virus in patients with dislipidemias
by: Jennifer Gotera, et al.
Published: (2019-12-01)

Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
by: Fernandez, E, et al.
Published: (2017)

A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus
by: Meihui Xu, et al.
Published: (2017-01-01)

Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
by: Jedhan Ucat Galula, et al.
Published: (2019-10-01)

Dengue virus serotype did not contribute to clinical severity or mortality in Taiwan’s largest dengue outbreak in 2015
by: Jih-Jin Tsai, et al.
Published: (2023-11-01)

Application of Next-Generation Sequencing to Reveal How Evolutionary Dynamics of Viral Population Shape Dengue Epidemiology
by: Hui-Ying Ko, et al.
Published: (2020-06-01)

Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.
by: Yi-Chin Fan, et al.
Published: (2015-10-01)

The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.
by: Bimmi Shrestha, et al.
Published: (2010-04-01)

Seroprevalence of Zika and Dengue Virus Antibodies among Migrant Workers, Taiwan, 2017
by: Guey Chuen Perng, et al.
Published: (2019-04-01)

Can Zika virus antibodies cross-protect against dengue virus?
by: Kevin K Ariën, et al.
Published: (2018-05-01)

Sculpting humoral immunity through dengue vaccination to enhance protective immunity
by: Wayne eCrill, et al.
Published: (2012-11-01)

Dengue virus targets the adaptor protein MITA to subvert host innate immunity.
by: Chia-Yi Yu, et al.
Published: (2012-01-01)

The Antiviral Activity of Varenicline against Dengue Virus Replication during the Post-Entry Stage
by: Ching-Lin Lin, et al.
Published: (2023-10-01)

Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus)
by: Nor Azila Muhammad Azami, et al.
Published: (2018-03-01)

Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes.
by: Kimberly Mattia, et al.
Published: (2011-01-01)

Seroprevalence of antibodies to dengue and chikungunya viruses in Thailand.
by: Sompong Vongpunsawad, et al.
Published: (2017-01-01)

The Human Antibody Response to Dengue Virus Infection
by: Aravinda M. de Silva, et al.
Published: (2011-11-01)

Antiviral Activity of Compound L3 against Dengue and Zika Viruses In Vitro and In Vivo
by: Fu-Kai Chuang, et al.
Published: (2020-06-01)

Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.
by: Sidhartha Chaudhury, et al.
Published: (2017-02-01)

Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus
by: J. A. Swanstrom, et al.
Published: (2016-09-01)

ANTIBODI MONOKLONAL TERHADAP ANTIGEN VIRUS DENGUE-3 (MONOCLONAL ANTIBODIES SPECIFIC FOR DENGUE-VRUS ANTIGEN)
by: Perpustakaan UGM, i-lib
Published: (1999)

Fever Screening at Airports and Imported Dengue
by: Pei-Yun Shu, et al.
Published: (2005-03-01)

Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.
by: Melissa A Edeling, et al.
Published: (2014-04-01)

Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.
by: Hui Zhao, et al.
Published: (2014-01-01)

Japanese Encephalitis DNA Vaccines with Epitope Modification Reduce the Induction of Cross-Reactive Antibodies against Dengue Virus and Antibody-Dependent Enhancement of Dengue Virus Infection
by: Tomohiro Kotaki, et al.
Published: (2022-08-01)

Correction: Therapeutic Efficacy of Antibodies Lacking Fc. Receptor Binding against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies.
by: Katherine L. Williams, et al.
Published: (2013-03-01)

Can Zika virus antibodies cross-protect against dengue virus? – Authors' reply
by: Guilherme S Ribeiro, et al.
Published: (2018-05-01)

Dengue Virus Impairs Mitochondrial Fusion by Cleaving Mitofusins.
by: Chia-Yi Yu, et al.
Published: (2015-12-01)